ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

This was a non-randomized, open-label, designed as a phase I / phase II trial to evaluate the safety and efficacy of azenosertib in combination with carboplatin and pembrolizumab in participants with metastatic triple negative breast cancer (TNBC) Azenosertib is a medication that targets WEE1, an important protein in tumor growth. The U.S. Food and Drug Administration (FDA) has not approved azenosertib as a treatment for metastatic triple-negative breast cancer. The FDA has approved carboplatin as a treatment option for metastatic triple-negative breast cancer and it is considered standard of care for breast cancer. The FDA has approved pembrolizumab for metastatic triple-negative breast cancer, but it is currently approved only for PD-L1 positive cancer. The research study procedures include screening for eligibility, study treatment visits, blood tests, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, and electrocardiograms (EKGs). It was expected that about 12-18 people would take part in the phase 1 portion. This study was terminated early prior to reaching Phase II (due to Zentalis's concern for toxicity safety from previously reported serious adverse events). Zentalis Pharmaceuticals funded this research study and provided Azenosertib. Merck supported this research study by providing pembrolizumab.